Gameto – Weekly Recap

Gameto, a women’s health biotechnology company focused on fertility and menopause, was the subject of notable media and industry attention this week, underscoring continued momentum across its fertility and ovarian biology platform. This weekly summary reviews the key developments and their potential implications for the company’s trajectory in reproductive medicine and women’s health.

A major highlight was an in-depth feature on Gameto in The Washington Post, which examined the company’s mission to transform fertility care by targeting ovarian biology and exploring the links between the ovaries, aging, and women’s long-term health. The article spotlighted Gameto’s lead therapy, Fertilo, an in vitro maturation platform designed to mature eggs outside the body. Fertilo aims to significantly reduce the need for hormone injections in IVF while maintaining comparable outcomes, based on early clinical experience. The coverage also profiled CEO and cofounder Dina Radenkovic Turner and detailed the scientific rationale for positioning ovarian function as a central lever for fertility, menopause, and healthy aging. Initial patient experiences from Australia and Latin America were highlighted, including cases where patients with challenging ovarian conditions and long histories of unsuccessful fertility treatments achieved pregnancies using the platform.

Previous disclosures, reiterated in recent updates, indicate that Fertilo is in final Phase III clinical trials, with more than 100 couples treated and at least nine births reported, including the first babies born through the platform outside the United States. Patients in pilot programs have reported fewer injections and reduced side effects compared with conventional IVF stimulation, suggesting a potential reduction in treatment burden if results are validated at scale. Gameto is leveraging major industry forums such as the American Society for Reproductive Medicine 2025 meeting to deepen engagement with clinicians, demonstrating Fertilo’s embryology workflow and integration into existing IVF laboratory processes.

Beyond fertility, Gameto is advancing Ameno, its next-generation hormone-sensitive ovarian implant aimed at menopause care. Supported by a $10 million non-dilutive grant from ARPA-H’s Sprint for Women’s Health Initiative, Ameno reflects the company’s broader strategy to use engineered ovarian-like cells and controlled hormone delivery to address menopause symptoms and long-term health risks. Gameto is also developing Deovo, an early-stage platform intended to support research and drug testing in ovarian disease. Collectively, these programs are backed by approximately $127 million in total funding, including a Series C round led by Overwater Ventures, and further validated by industry recognition such as the “Future of Fertility” award at the World Fertility Awards.

From a strategic perspective, the Washington Post feature enhances Gameto’s brand visibility and may support future fundraising and partnership discussions, even though it did not introduce new clinical or regulatory milestones. The company’s prospects remain contingent on the successful completion of late-stage Fertilo trials, regulatory approvals, reimbursement decisions, and adoption by fertility clinics and healthcare providers. Nonetheless, the combination of advancing clinical programs, non-dilutive funding, growing media presence, and industry recognition suggests a constructive week for Gameto, reinforcing its position as an emerging player in fertility, menopause, and ovarian biology–driven women’s health solutions.